• Claudia Satizabal, PhD, population health sciences and the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, and Sudha Seshadri, MD, neurology, director, of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases and senior investigator with the Framingham Heart Study, were quoted in this article.   Read More

  • Claudia Satizabal, PhD, population health sciences and the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, and Sudha Seshadri, MD, neurology, director, of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases and senior investigator with the Framingham Heart Study, were quoted in this article.   Read More

  • Claudia Satizabal, PhD, population health sciences and the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, and Sudha Seshadri, MD, neurology, director, of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases and senior investigator with the Framingham Heart Study, were quoted in this article.   Read More

  • Claudia Satizabal, PhD, population health sciences and the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, and Sudha Seshadri, MD, neurology, director, of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases and senior investigator with the Framingham Heart Study, were quoted in this article.   Read More

  • Claudia Satizabal, PhD, population health sciences and the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, and Sudha Seshadri, MD, neurology, director, of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases and senior investigator with the Framingham Heart Study, were quoted in this article.   Read More

  • The ´óÏó´«Ã½ was mentioned in this article.   Read More

  • Claudia Satizabal, PhD, population health sciences and the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, and Sudha Seshadri, MD, neurology, director, of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases and senior investigator with the Framingham Heart Study, were quoted in this article.   Read More

  • Claudia Satizabal, PhD, population health sciences and the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, and Sudha Seshadri, MD, neurology, director, of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases and senior investigator with the Framingham Heart Study, were quoted in this article.   Read More

  • More than one out of three people have pre-diabetes, characterized by abnormal blood sugar levels not yet in the diabetes range – and yet associated with significant increases in eye, kidney and neuropathic diseases, and risk of cardiovascular death.

  • Researchers hope to bring MRI biomarker to dementia risk stratification in patient care, clinical trials A ribbon of brain tissue called cortical gray matter grows thinner in people who go on to develop dementia, and this appears to be an accurate biomarker of the disease five to 10 years before symptoms appear, researchers from The […]